Loading...
Loading...
In a research report published Wednesday, Morgan Stanley analyst Bin Li upgraded Sinovac Biotech Ltd.
SVA to Equal-Weight and raised the price target from $1.40 to $3.40.
In the report, Morgan Stanley noted, "Positive results of EV71 clinical studies and lower R&D costs lead us to raise our 2013-14 estimates. SVA may not turn profitable until 2015 – but earnings visibility is clearly better, and risk-reward now looks balanced."
Sinovac closed Tuesday at $3.33 and is currently trading down 0.30% since market open hours.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in